Drug
M3814
M3814: highest development phase Phase 1, developed by Merck KGaA. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| M3814 100 mg NCT02516813 | Phase 1 | Advanced Solid Tumors |
Latest
No recent events.
Follow M3814 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.